Investment Risk Assessment: CURAS LIMITED

1. Risk Rating: MEDIUM

Justification: The company demonstrates solvency with positive net assets (£361,344) and a 20-year operating history, but exhibits concerning liquidity metrics and balance sheet concentration. The heavy reliance on stock (representing 64.6% of total assets) combined with declining cash reserves and a low quick ratio creates meaningful vulnerability. Accumulated losses on the P&L reserve, while improving, indicate historical profitability challenges.

2. Key Concerns

Concern 1: Extreme Stock Concentration Risk

Stock stands at £978,601, representing approximately 64.6% of total assets. For a pharmaceutical wholesaler, this is particularly concerning given product expiry risks, regulatory changes, and potential obsolescence. The quick ratio (excluding stock) is only 0.53x, meaning the company cannot cover current liabilities without liquidating stock—potentially at discounted values in a distressed scenario.

Concern 2: Deteriorating Cash Position

Cash has fallen significantly from £324,127 (2023) to £163,369 (2024)—a 49.6% decline. Simultaneously, debtors increased by 40.3% to £294,575. This combination suggests the company may be extending credit to customers while struggling to collect, creating cash flow pressure. The cash ratio of just 0.19x is insufficient to meet near-term obligations without stock conversion or debtor collection.

Concern 3: Elevated Leverage with Accumulated Losses

Total liabilities of £862,923 against net assets of £361,344 yields a debt-to-equity ratio of approximately 2.39x. The P&L reserve remains negative at (£36,176), indicating cumulative trading losses over the company's lifetime. While 2024 showed improvement (from £60,343 negative to £36,176 negative), the company has not yet eliminated its accumulated deficit despite two decades of operation.

3. Positive Indicators

• Consistent Net Asset Growth: Net assets have grown steadily from £117,311 (2015) to £361,344 (2024), demonstrating progressive equity building even if from a low base.

• Current Profitability: The P&L reserve improvement of approximately £24,167 in 2024 indicates the company generated a profit in the latest year, reversing the trend of accumulated losses.

• Regulatory Compliance: Accounts and confirmation statements are filed on time with no overdue status. The company has maintained active status throughout its 20-year history.

• Reducing Long-term Debt: Creditors due after more than one year decreased from £405,416 (2023) to £280,312 (2024), suggesting active debt repayment or reclassification.

• Established Market Position: Two decades in pharmaceutical wholesale suggests established supplier relationships and market knowledge.

4. Due Diligence Notes

Stock Quality and Provisioning

• Investigate the age profile of stock and adequacy of provisioning. Given pharmaceutical products have expiry dates, assess whether the £978,601 carrying value reflects potential write-downs.
• Request stock breakdown by category and age to understand obsolescence risk.

Debtor Collectability

• Obtain aged debtor analysis. The 40.3% increase in debtors year-on-year warrants scrutiny—are these credit terms being extended to maintain sales, or does this reflect genuine business growth?
• Assess bad debt provisioning adequacy.

Cash Flow Sustainability

• Request cash flow statements to understand the drivers behind the significant cash decline. Specifically, clarify whether this reflects investment in stock, extended customer credit, or operational cash burn.
• Review banking facilities—does the company have access to revolving credit or overdraft facilities?

Related Party Transactions

• The PSC register shows Casper Lykkegaard Kobke with 50-75% ownership and a "Persons with significant control statement" entry, suggesting potential additional PSCs not yet confirmed. Clarify full ownership structure.
• Given the family connection (Kobke as director, Kobke as secretary), assess whether related party transactions exist, particularly regarding the long-term creditor balances.

Profitability Trends

• The small company regime means no P&L account is filed. Request detailed trading results to understand margin trends, overhead control, and whether 2024's improvement is sustainable.
• Clarify whether the P&L reserve improvement reflects operational profit or one-off items.

Pharmaceutical Regulatory Compliance

• Verify compliance with MHRA wholesale distribution authorisation (WDA) requirements.
• Assess impact of any regulatory changes on stock valuation and business model sustainability.